28 Jun 2022
The Microbiology Society is delighted to announce that our sound science journal, Access Microbiology, has been re-launched as an innovative open research platform and is now open for submissions.
Voting is now open for elected members to the Impact and Influence Committee and Early Career Microbiologists (ECM) Forum Executive Committee. All eligible members will receive an email from Civica. The ballot will close on 17 June 2022.
Monkeypox is caused by the monkeypox virus, a DNA virus similar to the virus which caused smallpox in humans. Find resources relating to the virus, its spread, symptoms and treatments.
This issue highlights the importance of teaching and outreach in championing and advancing the understanding of microbiology.
Help support early and mid-career microbiologists who might, in turn, one day provide solutions to global challenges. Find out more and donate online.
The Council of the Microbiology Society is delighted to announce that in 2023 our founding journal, Microbiology, will be the first to make the transition from a hybrid model to fully Open Access.
Fee-free Open Access across our journals. Find out if you are eligible.
Access all content published by the Microbiology Society relating to SARS-CoV-2, the cause of COVID-19 in our digital hub.
29 June 2022
The latest edition of the Microbiology Society’s podcast, Microbe Talk, is now online. In the first of this two part episode, Eva Scholtus and Katie O’Connor from our Policy and Engagement team interview Colman, Raphael, Helen and Nat about their experiences as early career researchers during the SARS-CoV-2 pandemic.
They consider issues such as equality, diversity and inclusion, isolation and loneliness at work, managing heavy workloads, salary boundaries and the culture in academia.
29 June 2022
We are pleased to announce our first Focused Meeting of 2023, Vaccines as tools to combat antimicrobial resistance, in association with BactiVac, the Bacterial Vaccines Network. The meeting will take place on 27—28 February 2023 at Edgbaston Park Hotel and Conference Centre in Birmingham, UK.
27 June 2022
Staphylococcus aureus are opportunistic, Gram-positive bacteria, which are responsible for a large number of hospital and community-acquired infections. Current treatment options are limited to antibiotics, but with a rising number of multidrug-resistant strains the need to find alternative therapies is becoming increasingly apparent. One such treatment is via the inhibition of communication between the bacteria. Although these therapy options have previously been limited, research by a team from the University of Copenhagen has found that probiotics already available may offer the ability to reduce disease severity of S. aureus.